Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02242942 · FLOW

Participant flow

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia · Source last updated 2025-11-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
    id
    FG000
    title
    Obinutuzumab + Chlorambucil
  2. description
    Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
    id
    FG001
    title
    Obinutuzumab + Venetoclax
  3. description
    Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
    id
    FG002
    title
    Safety Run-in Obinutuzumab + Venetoclax
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        20
      3. group Id
        FG002
        num Subjects
        2
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        10
      3. group Id
        FG002
        num Subjects
        0
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        190
      2. group Id
        FG001
        num Subjects
        186
      3. group Id
        FG002
        num Subjects
        11
      type
      On-going in Study
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        216
      2. group Id
        FG001
        num Subjects
        216
      3. group Id
        FG002
        num Subjects
        13
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        214
      2. group Id
        FG001
        num Subjects
        212
      3. group Id
        FG002
        num Subjects
        13
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        216
      2. group Id
        FG001
        num Subjects
        216
      3. group Id
        FG002
        num Subjects
        13
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
    id
    FG000
    title
    Obinutuzumab + Chlorambucil
  2. description
    Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
    id
    FG001
    title
    Obinutuzumab + Venetoclax
  3. description
    Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
    id
    FG002
    title
    Safety Run-in Obinutuzumab + Venetoclax
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        20
      3. group Id
        FG002
        num Subjects
        2
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        8
      2. group Id
        FG001
        num Subjects
        10
      3. group Id
        FG002
        num Subjects
        0
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        190
      2. group Id
        FG001
        num Subjects
        186
      3. group Id
        FG002
        num Subjects
        11
      type
      On-going in Study
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        216
      2. group Id
        FG001
        num Subjects
        216
      3. group Id
        FG002
        num Subjects
        13
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        214
      2. group Id
        FG001
        num Subjects
        212
      3. group Id
        FG002
        num Subjects
        13
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        216
      2. group Id
        FG001
        num Subjects
        216
      3. group Id
        FG002
        num Subjects
        13
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice